SIR 2446M
Alternative Names: SIR-2446; SIR-2446MLatest Information Update: 28 Jan 2025
Price :
$50 *
At a glance
- Originator Sironax Aus Pty
- Class Antidementias
- Mechanism of Action RIPK1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alzheimer's disease; Multiple sclerosis
Most Recent Events
- 28 Jan 2025 No recent reports of development identified for phase-I development in Alzheimer's-disease(In volunteers) in Australia (PO, Capsule)
- 28 Jan 2025 No recent reports of development identified for phase-I development in Multiple-sclerosis(In volunteers) in Australia (PO, Capsule)
- 17 Mar 2022 CTPs 345327: updated intro, KDM and dev T for trial initiation